NEWS | VDyne

News Concept with Wooden Letters on Table in Bright Room.jpg

PRESS RELEASES

VDYNE Receives FDA Approval to Initiate the TRIVITA IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System

VDYNE Appoints Mike Buck as Chairman and CEO to Lead Next Phase of its TTVR Program

VDYNE to Present VISTA Study Data at 2025 EuroPCR Conference

VDYNE Announces 1st Patient Enrolled in VISTA Global Clinical Study for the Treatment of Tricuspid Regurgitation

VDYNE Announces First Patient Enrolled in VISTA US Early Feasibility Study for the Treatment of Tricuspid Regurgitation

VDYNE Announces $21M Financing Round to Enable First-in-Human Clinical Studies for Treatment of Tricuspid Regurgitation

The VDyne Valve System is an investigational product only that is presently undertaking human (clinical) feasibility studies. The VDyne System is not approved for commercial sale or use for the treatment of any health condition.